Institut Fuer Versorgungsforschung In Der Onkologie GbR — Clinical Trial Site

40 Registered trials

18 Currently recruiting

Organisation

Institut Fuer Versorgungsforschung In Der Onkologie GbR

Location

Koblenz, Germany

Identifier

ORG-100041075

Address

Neversstrasse 5, Sued, 56068, Germany

Departments

-
"Praxisklinik für Hämatologie und Onkologie"
Hämatologie und Onkologie
Hämatologie/Onkologie
Institut Fuer Versorgungsforschung In Der Onkologie GbR
Institut für Versorgungsforschung in der Onkologie
InVO - Institut für Versorgungsforschung in der Onkologie GbR
InVO- Institut fur Versorgungsforschung in der Onkologie GbR
Medical Oncology
N.A.
N/A
NA
Oncology
Oncology (Brustklinik)
Onkologie
Praxis fuer Haematologie und Onkologie
Praxis für Hämatologie und Onkologie
Praxis für Hämatologie und Onkologie Koblenz und InVO
Praxisklinik für Haematologie und Onkologie
Praxisklinik für Hämatologie und Onkologie
Praxisklinik für Hämatologie und Onkologie Koblenz
Private research facility

Clinical trials at this site (40)

Search interface

Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa… Ended

2023-506911-16-00 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVAN 5 2020-12-04
A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast… Ended

2024-514733-38-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2020-11-03
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Multiple Myeloma 5 2018-10-18
Obinutuzumab in marginal zone lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (OLYMP-1) Ended

2024-517476-38-00 Marginal Zone Lymphoma 4 2018-05-14
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small… Halted

2023-503298-39-00 Metastatic Non-Small Cell Lung Cancer (mNSCLC) 5 2024-06-13
CLL-Frail - A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients Ended

2023-507002-14-00 treatment-naïve or relapsed/refractory chronic lymphocy 4 2021-05-20
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC Ended

2023-509774-40-00 Stage IV lung cancer condition 5 2019-06-25
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (… Ended

2024-516904-40-00 Previously Untreated Diffuse large B-cell lymphoma (DLB 5 2018-03-27
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended

2023-506487-13-00 Hormone receptor-positive, her2-negative advanced/metas 5